BioSpace News Archive

Werewolf Therapeutics, Inc. announced that an abstract providing an update of the Company’s ongoing monotherapy and combination Phase 1/1b study of WTX-124, its interleukin 2 INDUKINE™ molecule, has been accepted for poster presentation at the 2024 American Society of Clinical Oncology Annual Meeting, taking place May 31 - June 4 in Chicago, Illinois.

Coherus BioSciences, Inc. announced the first presentation of clinical data for CHS-114, a highly selective cytolytic anti-CCR8 antibody, at the upcoming ASCO Annual Meeting, which will be held from May 31 to June 4, 2024, at McCormick Place in Chicago.

Precigen, Inc. (Nasdaq: PGEN) today announced clinical data from the pivotal Phase 2 study of PRGN-2012 AdenoVerse immunotherapy for the treatment of patients with recurrent respiratory papillomatosis (RRP) will be presented in a late-breaking oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

BioInvent International AB announced that two abstracts for its two leading assets, BI-1808 and BI-1206, have been selected for presentation at ASCO 2024.

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report first quarter 2024 financial results on Wednesday, May 8, 2024, after the U.S. financial markets close.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 9, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal second quarter ended March 31, 2024.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present or publish eight abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4, 2024 in Chicago.

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report financial results for the first quarter 2024 after market close on Tuesday, May 7, 2024.

CONMED Corporation (NYSE: CNMD) today announced financial results for the first quarter ended March 31, 2024.

Sonendo, Inc., a leading dental technology company and developer of the GentleWave® System, announced that it will report financial results for the first quarter 2024 after the market close on Wednesday, May 8th, 2024.